While the C6 cell line we use is widely recognized as a suitable choice for animal studies about high-grade gliomas, mutations in isocitrate dehydrogenase status, recognized as an important marker of human GBM prognosis [26,27,28], are not detected in the C6 cell line. This evidence concerns the gene IDH3A and glioma.